Core Viewpoint - Fosun Pharma's stock has seen a significant increase, rising over 6% and currently trading at 21.06 HKD, with a transaction volume of 299 million HKD, following the announcement of a licensing agreement with Expedition for the development and commercialization of the drug XH-S004 outside of China and Hong Kong [1] Group 1 - Fosun Pharma's subsidiary has signed a licensing agreement with Expedition, granting global rights for the development, production, and commercialization of the investigational product XH-S004, excluding China and Hong Kong [1] - Expedition will pay up to 120 million USD in non-refundable upfront payments and milestone payments based on development and regulatory achievements, as well as up to 525 million USD in sales milestone payments based on annual net sales in the licensed regions [1] - The DPP-1 inhibitor drug market is identified as having significant potential, with Fosun Pharma's XH-S004 currently in Phase II clinical trials for non-cystic fibrosis bronchiectasis and Phase I clinical trials for chronic obstructive pulmonary disease in China [1] Group 2 - Fosun Pharma has invested a total of 72 million RMB in research and development for the XH-S004 drug [1] - The licensing agreement is seen as a recognition of the company's innovative drug pipeline by foreign investment and research teams, which may lead to a reassessment of the company's innovative drug development pipeline [1]